Busca, AlessandroSalmanton-García, JonCorradini, PaoloMarchesi, FrancescoCabirta, AlbaDi Blasi, RobertaDulery, RemyLamure, SylvainFarina, FrancescaWeinbergerová, BarboraBatinić, JosipNordlander, AnnaLópez-García, AlbertoDrgoňa, ĽubošEspigado-Tocino, IldefonsoFalces-Romero, IkerGarcía-Sanz, RamónGarcía-Vidal, CarolinaGuidetti, AnnaKhanna, NinaKulasekararaj, AustinMaertens, JohanHoenigl, MartinKlimko, NikolaiKoehler, PhilippPagliuca, AntonioPassamonti, FrancescoCornely, Oliver APagano, Livio2023-05-032023-05-032022http://hdl.handle.net/10668/20249The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/COVID-19HumansImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-Lymphocytesresearch article34749396open access10.1182/bloodadvances.20210056162473-9537PMC8575532https://ashpublications.org/bloodadvances/article-pdf/6/7/2427/1887717/advancesadv2021005616.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575532/pdf